文献速递腹部CT

门静脉期CT肿瘤-实质对比增强比值对胰腺神经内分泌肿瘤的预后价值

Prognostic value of tumor-to-parenchymal contrast enhancement ratio on portal venous-phase CT in pancreatic neuroendocrine neoplasms.
PubMed 文献 · Eur Radiol · 2022-11-15

本研究回顾性纳入465例根治性切除的胰腺神经内分泌肿瘤患者作为开发队列,评估门静脉期CT肿瘤-实质对比增强比值(CER on PVP)预测无复发生存(RFS)的性能并确定最佳截断值,并在184例外部队列中验证。结果表明CER on PVP预测RFS和总生存(OS)的C指数分别为0.83和0.84,优于WHO分级和AJCC分期,提示其可作为无创术前预后工具。

要点

  • 门静脉期CT测量肿瘤-实质对比增强比值可用于术前预测胰腺神经内分泌肿瘤术后复发和生存。
  • CER on PVP预测RFS和OS的C指数(0.83、0.84)高于WHO分级和AJCC分期。
  • CER on PVP预测性能优于CT测量的肿瘤大小,可作为无创预后指标。

核心结论

  • 门静脉期CT肿瘤-实质对比增强比值对胰腺神经内分泌肿瘤术后生存的预测性能优于现行WHO分级和AJCC分期系统,有潜力作为无创术前预后工具。

研究设计与样本

  • 回顾性研究,开发队列465例接受 upfront 根治性切除的PanNEN患者,外部队列184例用于验证。
  • 使用Harrell C指数评估CER on PVP和CT测量的肿瘤大小(CT-Size)预测RFS的性能,并用多路划分算法确定最佳截断值。
  • 在测试队列中验证CER on PVP预测RFS和OS的性能,并与CT-Size、2019 WHO分类系统和第8版AJCC分期系统比较。

诊断标准与关键数值

  • 测试队列中CER on PVP预测RFS的C指数为0.83(95%CI 0.74-0.91),预测OS的C指数为0.84(95%CI 0.73-0.95)。
  • CT-Size预测RFS的C指数为0.71,预测OS的C指数为0.61。

临床应用与阅片要点

  • 可在术前门静脉期CT上测量肿瘤与胰腺实质的对比增强比值,辅助预测PanNEN术后复发风险。
  • CER on PVP预测性能优于肿瘤大小、WHO分级和AJCC分期,阅片时可将其作为补充预后指标。

局限性

  • 原文为回顾性研究设计,开发队列和测试队列的具体中心数、设备参数及参考标准未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We aimed to evaluate the prognostic value of tumor-to-parenchymal contrast enhancement ratio on portal venous-phase CT (CER on PVP) and compare its prognostic performance to prevailing grading and staging systems in pancreatic neuroendocrine neoplasms (PanNENs).

METHODS: In this retrospective study, data on 465 patients (development cohort) who underwent upfront curative-intent resection for PanNEN were used to assess the performance of CER on PVP and tumor size measured by CT (CT-Size) in predicting recurrence-free survival (RFS) using Harrell's C-index and to determine their optimal cutoffs to stratify RFS using a multi-way partitioning algorithm. External data on 184 patients (test cohort) were used to validate the performance of CER on PVP in predicting RFS and overall survival (OS) and compare its predictive performance with those of CT-Size, 2019 World Health Organization classification system (WHO), and the 8th American Joint Committee on Cancer staging system (AJCC).

RESULTS: In the test cohort, CER on PVP showed C-indexes of 0.83 (95% confidence interval [CI], 0.74-0.91) and 0.84 (95% CI, 0.73-0.95) for predicting RFS and OS, respectively, which were higher than those for the WHO (C-index: 0.73 for RFS [p = .002] and 0.72 for OS [p = .004]) and AJCC (C-index, 0.67 for RFS [p = .002] and 0.58 for OS [p = .002]). CT-Size obtained C-indexes of 0.71 for RFS and 0.61 for OS.

CONCLUSIONS: CER on PVP showed superior predictive performance on postoperative survival in PanNEN than current grading and staging systems, indicating its potential as a noninvasive preoperative prognostic tool.

KEY POINTS: • In pancreatic neuroendocrine neoplasms, the tumor-to-parenchymal enhancement ratio on portal venous-phase CT (CER on PVP) showed acceptable predictive performance of postoperative outcomes. • CER on PVP showed superior predictive performance of postoperative survival over the current WHO classification and AJCC staging system.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Park, Kim, Kim, et al. Prognostic value of tumor-to-parenchymal contrast enhancement ratio on portal venous-phase CT in pancreatic neuroendocrine neoplasms. Eur Radiol. 2022. PMID: 36378252. doi:10.1007/s00330-022-09235-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。